ID   UKF-NB-3rCDDP1000
AC   CVCL_M478
SY   UKF-NB-3 CDDP
DR   Wikidata; Q54990334
RX   PubMed=16151587;
RX   PubMed=17505515;
RX   PubMed=22170099;
RX   PubMed=24466371;
RX   PubMed=27517323;
RX   PubMed=27735941;
RX   PubMed=31581737;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=31581737
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 16,18
ST   D19S433: 14
ST   D21S11: 29,33.2
ST   D2S1338: 16,21
ST   D3S1358: 15,18
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 9,10
ST   FGA: 19,25
ST   Penta D: 8,15
ST   Penta E: 12
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9904 ! UKF-NB-3
SX   Female
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 13
//
RX   PubMed=16151587;
RA   Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr.,
RA   Michaelis M., Cinatl J., Eckschlager T.;
RT   "Characterization of drug-resistant neuroblastoma cell lines by
RT   comparative genomic hybridization.";
RL   Neoplasma 52:415-419(2005).
//
RX   PubMed=17505515; DOI=10.1038/sj.bjc.6603777;
RA   Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E.,
RA   Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.;
RT   "Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant
RT   neuroblastoma tumour cells to endothelium.";
RL   Br. J. Cancer 96:1699-1706(2007).
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=27517323; DOI=10.18632/oncotarget.11160;
RA   Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B.,
RA   Blight B.A., Cinatl J. Jr.;
RT   "ABCB1 as predominant resistance mechanism in cells with acquired
RT   SNS-032 resistance.";
RL   Oncotarget 7:58051-58064(2016).
//
RX   PubMed=27735941; DOI=10.1038/cddis.2016.257;
RA   Voges Y., Michaelis M., Rothweiler F., Schaller T., Schneider C.,
RA   Politt K., Mernberger M., Nist A., Stiewe T., Wass M.N., Rodel F.,
RA   Cinatl J. Jr.;
RT   "Effects of YM155 on survivin levels and viability in neuroblastoma
RT   cells with acquired drug resistance.";
RL   Cell Death Dis. 7:e2410.1-e2410.11(2016).
//
RX   PubMed=31581737; DOI=10.3390/cells8101194;
RA   Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R.,
RA   Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M.,
RA   Michaelis M.;
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
//